Genetic pharmacotherapy as an early CNS drug development strategy: testing glutaminase inhibition for schizophrenia treatment in adult mice

Genetic pharmacotherapy as an early CNS drug development strategy: testing glutaminase inhibition for schizophrenia treatment in adult mice

Genetic pharmacotherapy is an early drug development strategy for the identification of novel CNS targets in mouse models prior to the development of specific ligands. Here for the first time, we have implemented this strategy to address the potential therapeutic value of a glutamate-based pharmacot...

Full description

Bibliographic Details
Main Authors: Susana eMingote, Justine eMasson, Celia eGellman, Gretchen Miller Thomsen, Chyuan-Sheng eLin, Robert J. Merker, Inna eGaisler-Salomon, Yvonne eWang, Rachel eErnst, Rene eHen, Stephen eRayport
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-01-01
Series:Frontiers in Systems Neuroscience
Subjects:
Glutamine
Glutamate
antipsychotic
GLS1
Tamoxifen-inducible
allelic abundance
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnsys.2015.00165/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fnsys.2015.00165/full

Similar Items